TY - JOUR
T1 - Prostate cancer and antidepressants
T2 - A nationwide population-based nested case-control study
AU - Lin, Wei Yu
AU - Chen, Vincent Chin Hung
AU - Chiu, Wei Che
AU - Yim, Samantha J.
AU - Ho, Peter T.
AU - McIntyre, Roger S.
AU - Lu, Mong Liang
AU - Wu, Shui I.
N1 - Funding Information:
The present study is supported in part by the Ministry of Science and Technology , R.O.C. (MOST 102-2314-B-040-004-MY3 ), the Chang Gung Medical Foundation , Chiayi Chang Gung Memorial Hospital ( CMRPG6E0261 ). The funders supported the application and usage of the NHIRD and had no role in study design, data collection, or analysis.
Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Background We aimed to evaluate the association between antidepressant and prostate cancer by comparing exposures to antidepressants between those with and without prostate cancer. Methods A nationwide insurance claims database was used to identify our case subjects. Age- and gender-matched controls were selected at a 1:5 ratio. Conditional logistic regression model was used. Results 11,515 patients with prostate cancer were identified and matched with 55,373 controls. No increased associations between prostate cancer and most classes of antidepressants were found. However, a positive association with adjusted odds ratios ranged from 1.20 to 1.35 was noted in different doses of imipramine. Nevertheless, this association became statistically insignificant at higher cumulative doses. Conclusions Our results indicate that there is no association between mechanistically dissimilar antidepressants and increased hazard for prostate cancer.
AB - Background We aimed to evaluate the association between antidepressant and prostate cancer by comparing exposures to antidepressants between those with and without prostate cancer. Methods A nationwide insurance claims database was used to identify our case subjects. Age- and gender-matched controls were selected at a 1:5 ratio. Conditional logistic regression model was used. Results 11,515 patients with prostate cancer were identified and matched with 55,373 controls. No increased associations between prostate cancer and most classes of antidepressants were found. However, a positive association with adjusted odds ratios ranged from 1.20 to 1.35 was noted in different doses of imipramine. Nevertheless, this association became statistically insignificant at higher cumulative doses. Conclusions Our results indicate that there is no association between mechanistically dissimilar antidepressants and increased hazard for prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=85036503412&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85036503412&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2017.11.039
DO - 10.1016/j.jad.2017.11.039
M3 - Article
AN - SCOPUS:85036503412
SN - 0165-0327
VL - 227
SP - 834
EP - 839
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
ER -
